World of DTC Marketing
MARCH 17, 2021
Pharma has gone to court again and again to delay generic competition of biologic drugs. One company AbbVie has used the courts to stop competition of its top drug Humira. Another biologic, Enbrel, on the market since 1998, will not have its $5 billion in sales challenged until the end of 2028.
Spotio
APRIL 4, 2023
billion by 2028. That means competition is fierce, especially in high-growth locations. You need a proven system to connect with quality prospects, earn their trust, and close deals. Craft A Value-Based Sales Pitch Why should your prospects hire your company to install or fix their roofs? The industry grew by 2.7%
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
APRIL 20, 2023
The district court had previously blocked Sandoz and Zydus from producing, selling, offering to sell, or importing generic versions of Otezla until February 2028. This is one of several patent infringement cases Amgen has pursued in recent years to stave competition. billion worth of the drug worldwide. Patent No.
Pharmaceutical Technology
JUNE 20, 2023
GlobalData is the parent company of Pharmaceutical Technology DICE’s novel oral therapeutic candidates positioned it as an attractive prospect for acquisition. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Pharmaceutical Technology
JUNE 16, 2023
As it stands, GlobalData analysis predicts that Keytruda’s yearly revenue will hit almost $35bn in 2028, up from $21bn in 2022. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape.
Expert insights. Personalized for you.
186 
Let's personalize your content